Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

StatusActive, Not Recruiting

PhasePhase 2

SponsorMclean Hospital

Started2024-02-27

View on ClinicalTrials.gov ↗

Trial flagged as At Risk

Primary completion moved at least 5 months later across 2 updates Jun 2026 → Dec 2026

See other at-risk trials from Mclean Hospital

Amendment history

2026-10-01

Enrollment closed, study ongoing

Primary completion pushed: 2026-10 → 2026-12

Completion pushed: 2026-10 → 2026-12

2026-07-17

Study Status v4

Primary completion pushed: 2026-06 → 2026-10

Completion pushed: 2026-06 → 2026-10

2026-03-24

Study Status, Oversight v3

Re-verified, no change to tracked fields

2025-03-14

Study Status v2

Start dateestimated 2024-12→confirmed 2024-02-27

2024-11-18

Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start date2024-08→2024-12

Study sites0→1

2024-06-21

Original filing

Mclean Hospital

53 trials monitored

See 1 trial at risk

Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. This project will provide information that does not currently exist on the potential efficacy of a cannabinoid-based sublingual product for endometriosis.

Trial Details

NCT Number	NCT06477406
Lead Sponsor	Mclean Hospital Collaborators: Massachusetts Life Sciences Center
Conditions	Endometriosis
Enrollment	30 participants
Start Date	2024-02-27
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-30